

3. (currently amended) Method according to Use as in claim 1 wherein the harmful effects of UVB radiation are ~~or 2 to manufacture a medicinal product having protective action against the photo immunosuppressive effect induced by UVB radiation on Langerhans cells.~~

4. (currently amended) Method according to claim 1 ~~Use as in any of the preceding claims, wherein~~ characterized in that the R1 and R2 groups, independently of each other, represent a hydrogen atom or a C₁-C₇ alkyl group.

5. (currently amended) Method according to claim 1 ~~Use as in any of the preceding claims wherein~~ characterized in that the R3 group represents NH₂.


6. (currently amended) Method according to ~~Use as in claim 5, wherein~~ characterized in that the derivative of biguanide is metformin, ~~advantageously in the form of a hydrochloride.~~

7. (Cancelled)

8. (Cancelled)

9. (currently amended) Method according to claim 1 ~~Use as in any of the preceding claims, wherein~~ characterized in that the derivative of biguanide or its pharmaceutically acceptable salt is combined with at least one other active ingredient.

10. (currently amended) Method for protecting the skin against the adverse and/or displeasing effects of UVB radiation comprising the administration to a patient in need thereof of an effective amount of ~~cosmetic use of~~ a biguanide derivative of following general formula I:



(I)

in which:

the R1 and R2 groups, independently of each other, represent a hydrogen atom, a C₁-C₇ alkyl group, a cycloalkyl


group, a heterocycle, a C₂-C₇ alkenyl group, an aryl group, an aralkyl group, an aryloxyalkyl group or a heteroaryl group,

or R₁ and R₂ taken together represent a C₂-C₇ alkylene possibly containing one or more heteroatoms,

and the R₃ group represents a primary, secondary or tertiary amine

or its pharmaceutically acceptable salt

with the exception of the compound of formula:



11. (New) Method according to claim 6 wherein the metformin is in the form of a hydrochloride.

12. (New) Method according to claim 1 wherein the biguanide derivative or its pharmaceutically acceptable salt are applied locally to the patient in need thereof.

13. (New) Method according to claim 1 wherein the biguanide derivative or its pharmaceutically acceptable salt are used in the form of a medicinal product which contains a suitable excipient and wherein the amount of biguanide derivative or of its pharmaceutically acceptable salt in said medicinal product is of 0.02 to 2 % by weight.